S&P 500   4,297.29 (+0.22%)
DOW   33,466.77 (-0.12%)
QQQ   360.45 (+0.61%)
AAPL   173.42 (+1.29%)
MSFT   318.79 (+0.96%)
META   304.78 (+1.52%)
GOOGL   133.50 (+2.02%)
AMZN   129.16 (+1.60%)
TSLA   251.25 (+0.41%)
NVDA   448.69 (+3.15%)
NIO   8.81 (-2.54%)
BABA   86.19 (-0.63%)
AMD   102.33 (-0.48%)
T   14.85 (-1.13%)
F   12.26 (-1.29%)
MU   67.77 (-0.38%)
CGC   0.79 (+1.00%)
GE   109.37 (-1.07%)
DIS   81.02 (-0.04%)
AMC   7.93 (-0.75%)
PFE   33.37 (+0.60%)
PYPL   58.75 (+0.50%)
NFLX   380.71 (+0.82%)
S&P 500   4,297.29 (+0.22%)
DOW   33,466.77 (-0.12%)
QQQ   360.45 (+0.61%)
AAPL   173.42 (+1.29%)
MSFT   318.79 (+0.96%)
META   304.78 (+1.52%)
GOOGL   133.50 (+2.02%)
AMZN   129.16 (+1.60%)
TSLA   251.25 (+0.41%)
NVDA   448.69 (+3.15%)
NIO   8.81 (-2.54%)
BABA   86.19 (-0.63%)
AMD   102.33 (-0.48%)
T   14.85 (-1.13%)
F   12.26 (-1.29%)
MU   67.77 (-0.38%)
CGC   0.79 (+1.00%)
GE   109.37 (-1.07%)
DIS   81.02 (-0.04%)
AMC   7.93 (-0.75%)
PFE   33.37 (+0.60%)
PYPL   58.75 (+0.50%)
NFLX   380.71 (+0.82%)
S&P 500   4,297.29 (+0.22%)
DOW   33,466.77 (-0.12%)
QQQ   360.45 (+0.61%)
AAPL   173.42 (+1.29%)
MSFT   318.79 (+0.96%)
META   304.78 (+1.52%)
GOOGL   133.50 (+2.02%)
AMZN   129.16 (+1.60%)
TSLA   251.25 (+0.41%)
NVDA   448.69 (+3.15%)
NIO   8.81 (-2.54%)
BABA   86.19 (-0.63%)
AMD   102.33 (-0.48%)
T   14.85 (-1.13%)
F   12.26 (-1.29%)
MU   67.77 (-0.38%)
CGC   0.79 (+1.00%)
GE   109.37 (-1.07%)
DIS   81.02 (-0.04%)
AMC   7.93 (-0.75%)
PFE   33.37 (+0.60%)
PYPL   58.75 (+0.50%)
NFLX   380.71 (+0.82%)
S&P 500   4,297.29 (+0.22%)
DOW   33,466.77 (-0.12%)
QQQ   360.45 (+0.61%)
AAPL   173.42 (+1.29%)
MSFT   318.79 (+0.96%)
META   304.78 (+1.52%)
GOOGL   133.50 (+2.02%)
AMZN   129.16 (+1.60%)
TSLA   251.25 (+0.41%)
NVDA   448.69 (+3.15%)
NIO   8.81 (-2.54%)
BABA   86.19 (-0.63%)
AMD   102.33 (-0.48%)
T   14.85 (-1.13%)
F   12.26 (-1.29%)
MU   67.77 (-0.38%)
CGC   0.79 (+1.00%)
GE   109.37 (-1.07%)
DIS   81.02 (-0.04%)
AMC   7.93 (-0.75%)
PFE   33.37 (+0.60%)
PYPL   58.75 (+0.50%)
NFLX   380.71 (+0.82%)
Followed 110 TimesTop FollowedTop-Rated StocksTop-RatedMost-Upgraded StocksMost-Upgraded
NYSE:LLY

Eli Lilly and Company (LLY) Stock Forecast, Price & News

$532.74
-4.39 (-0.82%)
(As of 11:10 AM ET)
Compare
Today's Range
$528.05
▼
$536.83
50-Day Range
$449.16
▼
$599.54
52-Week Range
$309.20
▼
$601.84
Volume
647,585 shs
Average Volume
2.99 million shs
Market Capitalization
$505.72 billion
P/E Ratio
74.09
Dividend Yield
0.85%
Price Target
$532.78
ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Eli Lilly and Company MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
0.1% Downside
$532.78 Price Target
Short Interest
Healthy
0.74% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
0.71mentions of Eli Lilly and Company in the last 14 days
Based on 22 Articles This Week
Insider Trading
Selling Shares
$20.95 B Sold Last Quarter
Proj. Earnings Growth
33.23%
From $9.84 to $13.11 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

79th out of 969 stocks

Pharmaceutical Preparations Industry

21st out of 453 stocks

See Top Rated MarketRank™ Stocks Here

LLY stock logo

About Eli Lilly and Company (NYSE:LLY) Stock

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

LLY Price History

LLY Stock News Headlines

September 20, 2023 | marketbeat.com
Flee to Healthcare Stocks if Recession Rears its Head? (LLY)
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
September 19, 2023 | marketbeat.com
Could Ely Lilly Be the Best Pharma Stock to Own Now and Forever?
Eli Lilly & Co. stock has been on a tear, trading up 57.7% year-to-date on the strength of its industry-leading medications and highly-anticipated pipeline
October 2, 2023 | PressReach (Ad)
Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
September 18, 2023 | marketbeat.com
Can These 3 Healthcare Dividend Stocks Deliver Income Growth? (LLY)
Healthcare-sector dividend payers Pfizer, Medtronic, and Gilead all boosted shareholder payouts and trade at low multiples relative to potential price gains.
October 2, 2023 | msn.com
Eli Lilly Gets FDA Letter About Eczema Drug Concerns. The Stock Shrugs.
October 2, 2023 | markets.businessinsider.com
Eli Lilly: FDA Issues CRL For Lebrikizumab BLA Related To Third-party Manufacturing Organization
October 2, 2023 | finance.yahoo.com
Eli Lilly Gets FDA Letter About Eczema Drug Concerns
September 30, 2023 | barrons.com
Eli Lilly & Co.
October 2, 2023 | PressReach (Ad)
Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
September 29, 2023 | msn.com
Goldman Sachs' Chris Shibutani talks his top biotech picks including Eli Lilly and Pfizer
September 29, 2023 | msn.com
Eli Lilly, Former Employee Settle Lawsuit Concerning Manufacturing Dispute
September 29, 2023 | finance.yahoo.com
3 Stocks to Focus on as Demand for Obesity Drugs Booms
September 29, 2023 | finance.yahoo.com
Upstart Weight-Loss Drugmaker Jumps 75% on Strong Test Results
September 29, 2023 | finance.yahoo.com
Structure Stock Soars. Its Obesity Pill Could Challenge Lilly, Novo.
September 29, 2023 | finance.yahoo.com
Eli Lilly, Silfab Solar among projects helping drive a manufacturing revival in Charlotte region
September 28, 2023 | finance.yahoo.com
Eli Lilly settles whistleblower lawsuit over manufacturing problems
September 28, 2023 | finance.yahoo.com
Lilly Canada to Clean Up Shorelines and Be Citizen Scientists for Global Day of Service
September 28, 2023 | finance.yahoo.com
Global Cancer Pain Market 2023-2028: Eli Lilly & Company and Johnson & Johnson at the Forefront of Personalized Pain Management for Cancer Patients
September 27, 2023 | msn.com
Signal: Eli Lilly’s $176.5m Teva patent infringement loss overturned in US
September 27, 2023 | msn.com
Eli Lilly (LLY) Stock Moves -0.41%: What You Should Know
September 26, 2023 | msn.com
Boehringer and Lilly gain FDA approval for kidney disease therapy
September 26, 2023 | finance.yahoo.com
Wall Street Expects Historic Sales from Ozempic and Other Obesity Treatments
September 26, 2023 | finance.yahoo.com
2 Magnificent Dividend Stocks to Buy Right Now
September 25, 2023 | finance.yahoo.com
FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease
September 25, 2023 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Centessa Pharmaceuticals (CNTA)
September 22, 2023 | investorplace.com
Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend
September 22, 2023 | marketwatch.com
Eli Lilly, Boehringer Ingelheim Get FDA OK for Jardiance in Chronic Kidney Disease
See More Headlines
Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.

LLY Company Calendar

Last Earnings
8/08/2023
Ex-Dividend for 9/8 Dividend
8/14/2023
Dividend Payable
8/15/2023
Dividend Payable
9/08/2023
Today
10/02/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023
Ex-Dividend for 8/15 Dividend
1/01/2100
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSE:LLY
CUSIP
53245710
CIK
59478
Web
www.lilly.com
Phone
(317) 276-2000
Fax
317-276-4878
Employees
39,000
Year Founded
1876

Price Target and Rating

Average Stock Price Forecast
$532.78
High Stock Price Forecast
$640.00
Low Stock Price Forecast
$278.00
Forecasted Upside/Downside
-0.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
21 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$7.19
Trailing P/E Ratio
74.71
Forward P/E Ratio
54.59
P/E Growth
2.21
Net Income
$6.24 billion
Net Margins
22.01%
Pretax Margin
24.67%
Return on Equity
65.00%
Return on Assets
13.76%

Debt

Debt-to-Equity Ratio
1.63
Current Ratio
1.13
Quick Ratio
0.87

Sales & Book Value

Annual Sales
$28.54 billion
Price / Sales
17.87
Cash Flow
$9.17 per share
Price / Cash Flow
58.60
Book Value
$11.34 per share
Price / Book
47.37

Miscellaneous

Outstanding Shares
949,290,000
Free Float
948,061,000
Market Cap
$509.89 billion
Optionable
Optionable
Beta
0.32

Social Links

Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. David A. RicksMr. David A. Ricks (Age 55)
    Chairman, CEO & Pres
    Comp: $4.42M
  • Ms. Anat AshkenaziMs. Anat Ashkenazi (Age 50)
    Exec. VP & CFO
    Comp: $2.13M
  • Dr. Daniel M. Skovronsky M.D. (Age 49)
    Ph.D., Exec. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Laboratories
    Comp: $2.72M
  • Ms. Anat Hakim J.D. (Age 54)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $1.98M
  • Mr. Patrik Jonsson (Age 56)
    EVP, Chief Customer Officer, Pres of Lilly USA & Lilly Immunology
    Comp: $1.67M
  • Mr. Donald A. ZakrowskiMr. Donald A. Zakrowski
    Chief Accounting Officer & VP of Fin.
  • Mr. Diogo Rau
    EVP & Chief Information and Digital Officer
  • Mr. Alonzo WeemsMr. Alonzo Weems (Age 52)
    EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer
  • Ms. Leigh Ann Pusey (Age 60)
    Exec. VP of Corp. Affairs & Communications
  • Mr. Eric Dozier (Age 56)
    Exec. VP of HR & Diversity

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













LLY Stock - Frequently Asked Questions

Should I buy or sell Eli Lilly and Company stock right now?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last year. There are currently 1 sell rating, 1 hold rating and 19 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LLY shares.
View LLY analyst ratings or view top-rated stocks.

What is Eli Lilly and Company's stock price forecast for 2023?

21 Wall Street research analysts have issued 1 year price targets for Eli Lilly and Company's stock. Their LLY share price forecasts range from $278.00 to $640.00. On average, they predict the company's share price to reach $532.78 in the next year. This suggests that the stock has a possible downside of 0.8%.
View analysts price targets for LLY or view top-rated stocks among Wall Street analysts.

How have LLY shares performed in 2023?

Eli Lilly and Company's stock was trading at $365.84 at the start of the year. Since then, LLY stock has increased by 46.8% and is now trading at $537.13.
View the best growth stocks for 2023 here.

When is Eli Lilly and Company's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our LLY earnings forecast.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) issued its earnings results on Tuesday, August, 8th. The company reported $2.11 EPS for the quarter, topping the consensus estimate of $1.98 by $0.13. The business earned $8.31 billion during the quarter, compared to analyst estimates of $7.58 billion. Eli Lilly and Company had a trailing twelve-month return on equity of 65.00% and a net margin of 22.01%. The business's revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period in the prior year, the company posted $1.25 earnings per share.
Read the conference call transcript.

How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?

Eli Lilly and Company declared a quarterly dividend on Monday, June 26th. Shareholders of record on Tuesday, August 15th will be given a dividend of $1.13 per share on Friday, September 8th. This represents a $4.52 annualized dividend and a yield of 0.84%. The ex-dividend date of this dividend is Monday, August 14th.
Read our dividend analysis for LLY.

What ETFs hold Eli Lilly and Company's stock?

ETFs with the largest weight of Eli Lilly and Company (NYSE:LLY) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE), Harbor Health Care ETF (MEDI), Invesco S&P 500 Momentum ETF (SPMO), Horizon Kinetics Medical ETF (MEDX), Goldman Sachs Future Health Care Equity ETF (GDOC), iShares U.S. Healthcare ETF (IYH), Health Care Select Sector SPDR Fund (XLV) and Vanguard Health Care Index Fund (VHT).

Is Eli Lilly and Company a good dividend stock?

Eli Lilly and Company (NYSE:LLY) pays an annual dividend of $4.52 per share and currently has a dividend yield of 0.84%. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 62.87%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LLY will have a dividend payout ratio of 34.48% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.

What guidance has Eli Lilly and Company issued on next quarter's earnings?

Eli Lilly and Company updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of $9.70-$9.90 for the period, compared to the consensus earnings per share estimate of $8.71. The company issued revenue guidance of $33.40 billion-$33.90 billion, compared to the consensus revenue estimate of $31.44 billion.

What is David A. Ricks' approval rating as Eli Lilly and Company's CEO?

399 employees have rated Eli Lilly and Company Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.

What other stocks do shareholders of Eli Lilly and Company own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and Company investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

What is Eli Lilly and Company's stock symbol?

Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How do I buy shares of Eli Lilly and Company?

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eli Lilly and Company's stock price today?

One share of LLY stock can currently be purchased for approximately $537.13.

How much money does Eli Lilly and Company make?

Eli Lilly and Company (NYSE:LLY) has a market capitalization of $509.89 billion and generates $28.54 billion in revenue each year. The company earns $6.24 billion in net income (profit) each year or $7.19 on an earnings per share basis.

How many employees does Eli Lilly and Company have?

The company employs 39,000 workers across the globe.

Does Eli Lilly and Company have any subsidiaries?
The following companies are subsidiares of Eli Lilly and Company: 1096401 B.C. Unlimited Liability Company, ARMO Biosciences Inc., Acanthas Pharma Inc., Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma Inc., Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Compania Farmaceutica Eli Lilly de Centro America S.A., Dermira, Dermira Canada, Dermira Inc., Devices for Vascular Intervention(DVI), Disarm Therapeutics, Disarm Therapeutics, Disarm Therapeutics Inc., Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc., Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, LDH I Corporation, Lilly (Shanghai) Management Co. Ltd., Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly Centre for Clinical Pharmacology PTE. LTD., Lilly China Research and Development Co. Ltd, Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Loxo Oncology Inc., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Petra Pharma Corporation, Pharmaserve-Lilly S.A.C.I., Pharmaserve-Lilly S.A.C.I., Physio-Control, Prevail Therapeutics Inc., Protomer Technologies, SGX Pharmaceuticals, SGX Pharmaceuticals Inc., Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.
Read More
How can I contact Eli Lilly and Company?

Eli Lilly and Company's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The official website for the company is www.lilly.com. The company can be reached via phone at (317) 276-2000, via email at johnson_philip_l@lilly.com, or via fax at 317-276-4878.

This page (NYSE:LLY) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -